Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...
Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.
MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster ...
Zacks.com on MSN3d
Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline SetbackThe third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY ...
AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...
VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...
Merck & Co. Inc. has in-licensed Lanova Medicines Ltd.’s PD-1/VEGF bispecific antibody LM-299 in a deal worth up to $2.7 billion in a move to bolster its Keytruda (pembrolizumab) fortress. Under terms ...
As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug ...
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based ...
Merck (MRK) and LaNova Medicines, a privately held clinical-stage biotechnology company, announced that Merck has entered into an exclusive ...
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...
Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback